---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-075871"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T18:53:23.029119+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge

## Summary
- Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.
- Company will record a pre-tax charge of approximately $145M in Q1 2025, funded by cash on hand.
- Settlement remains subject to court approval; Jazz denies all alleged wrongdoing.
- The settlement resolves the majority of claims in the multi-district litigation; additional settlements with remaining plaintiffs may be significant.

## SEC filing metadata
- accession: 0001193125-25-075871
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525075871/0001193125-25-075871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525075871/d901769d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-075871
- JSON: https://secwatch.observer/filing/0001193125-25-075871.json
- Plain text: https://secwatch.observer/filing/0001193125-25-075871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.